RY
Therapeutic Areas
Nxera Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HTL0018318 | Neurological Disorders (e.g., Cognitive Impairment) | Phase 1 |
| HTL'149 | Schizophrenia | Phase 1 |
| HTL0014242 | Neurological Disorders | Preclinical |
| HTL0039732 | Undisclosed | Preclinical |
| GPR52 Agonist | Schizophrenia | Preclinical |
| GPR35 Agonist | Inflammatory Bowel Disease (IBD) | Preclinical |
| EP4 Antagonist | Oncology Immunotherapy | Preclinical |
| Fexuprazan | Erosive Esophagitis (GERD) | Phase 3 |
Leadership Team at Nxera Pharma
CC
Chris Cargill
President, Chief Executive Officer, Representative Director
ST
Shinichi Tamura
Founder and Chairman of the Board
ML
Mickey Lee
Chief Financial Officer, Senior Vice President of Corporate Development
MB
Matt Barnes
President of Heptares Therapeutics, Head of UK R&D
MW
Malcolm Weir
Executive Vice President, Head of Research & Development Strategy
MC
Miles Congreve
Chief Scientific Officer, Sosei Heptares
FM
Fiona Marshall
Chief Scientific Officer & Founder, Sosei Heptares
TT
Tim Tasker
Chief Medical Officer
HI
Hironoshin Ishii
Independent Director
HO
Hiroko Ohta
Independent Director